Argent Biopharma Limited Company Presentation

RNS Number : 5463U

Argent Biopharma Limited

01 July 2024

 

 

1 July 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Company Presentation

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, announces the publication of its Company Presentation for June 2024 which may be accessed via the following link:

 

https://www.investi.com.au/api/announcements/rgt/ed231bfb-b84.pdf

 

 

-Ends-

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]	Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Corporate Broker Shore Capital Toby Gibbs / James Thomas / Lucy Bowden [phone]

 

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is a Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to providing accessible medical treatments for unmet medical needs, to bridge the gap where medical solutions currently fall short.  The Group focuses on the Multidisciplinary method with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning to the Central nervous system ("CNS") and Immunology treatments.

 

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCRBMATMTAMMII